Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen A Goldman

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
JAMA|August 23, 2002
Postmarketing surveillance and black box warningsStephen A Goldman
Drug Safety|July 31, 2016
Causality Assessment in Premarketing Drug Clinical Trials: Regulatory Evolution in the USA and Ongoing ConcernsStephen A Goldman
Drug Safety|May 25, 2004
Communication of medical product risk: how effective is effective enough?Stephen A Goldman
Food and Drug Law Journal|October 6, 2007
U.S. postmarketing pharmacovigilance compliance in the midst of regulatory uncertaintyStephen A Goldman
Drug Safety|December 6, 2011
Terminological challenges in safety surveillanceAndrew Bate, Elliot G Brown, Stephen A Goldman, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
JAMA|August 23, 2002
Postmarketing surveillance and black box warningsStephen A Goldman
Drug Safety|July 31, 2016
Causality Assessment in Premarketing Drug Clinical Trials: Regulatory Evolution in the USA and Ongoing ConcernsStephen A Goldman
Drug Safety|May 25, 2004
Communication of medical product risk: how effective is effective enough?Stephen A Goldman
Food and Drug Law Journal|October 6, 2007
U.S. postmarketing pharmacovigilance compliance in the midst of regulatory uncertaintyStephen A Goldman
Drug Safety|December 6, 2011
Terminological challenges in safety surveillanceAndrew Bate, Elliot G Brown, Stephen A Goldman, et al.
Pageof 1